All in the Levels—Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer
Satya Das(AstraZeneca (United States)), Kristen K. Ciombor(Vanderbilt University Medical Center), Shemeka Davis(Vanderbilt University Medical Center), Sarah K Cimino(Vanderbilt University Medical Center)
Cited by 3
Related Papers
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846
Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2024|333
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
|Journal of the National Comprehensive Cancer Network|2024|244